Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2024-08-01 17:20:00
Oslo, August 1, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage
biotechnology company developing immunotherapeutic cancer vaccines, today
announced that an update from the Phase II NIPU trial (NCT04300244
(https://clinicaltrials.gov/study/NCT04300244)) in patients with malignant
mesothelioma will be presented in a poster presentation at the 2024 ESMO
Congress. The conference will be held in Barcelona, Spain from September
13-17, 2024.
Poster Presentation Details:
Title: Updated survival and vaccine response from the NIPU trial